MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Vanda Pharmaceuticals Inc

Uždarymo kaina

4.48 -2.61

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

4.44

Max

4.58

Pagrindiniai rodikliai

By Trading Economics

Pajamos

412K

-4.9M

Pardavimai

5.5M

53M

Pelnas, tenkantis vienai akcijai

-0.084

Pelno marža

-9.236

Darbuotojai

368

EBITDA

727K

-8.3M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+251.81% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-05-07

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

63M

315M

Ankstesnė atidarymo kaina

7.09

Ankstesnė uždarymo kaina

4.48

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Vanda Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2024-04-02 23:54; UTC

Karštos akcijos

Stocks to Watch: Intel, Vanda Pharmaceuticals, OneMedNet

2024-04-02 22:59; UTC

Pagrindinės rinkos jėgos

Vanda Pharmaceuticals Shares Jump 17% After FDA Approved Fanapt for Bipolar I Disorder

Akcijų palyginimas

Kainos pokytis

Vanda Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

251.81% į viršų

12 mėnesių prognozė

Vidutinis 16.5 USD  251.81%

Aukščiausias 20 USD

Žemiausias 13 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Vanda Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

2

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

4.58 / 4.77Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.